Patients with heritable cancer syndromes characterized by germline PTEN mutations (termed PTEN hamartoma tumor syndrome, PHTS) benefit from PTEN-enabled cancer risk assessment and clinical management. The gene discussed is PTEN; the disease is PTEN hamartoma tumor syndrome.